# Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab

> **NCT01927757** · PHASE4 · TERMINATED · sponsor: **Amgen** · enrollment: 90 (actual)

## Conditions studied

- Moderate to Severe Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Etanercept
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT01927757
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05-06
- **Primary completion:** 2015-06-11
- **Final completion:** 2015-06-11
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** Business decision due to slow enrollment
- **Last updated:** 2018-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01927757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01927757, "Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01927757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*